Microdosing psilocybin for cluster headache involves the administration of sub-perceptual doses of this serotonergic psychedelic, which is thought to modulate 5-HT2A receptor activity and potentially disrupt aberrant neural signaling associated with headache pathogenesis. The therapeutic mechanism may involve neuroplastic changes and alterations in brain connectivity, with anecdotal and emerging clinical evidence suggesting significant reductions in cluster headache frequency, intensity, and duration.